Skip to content
Catalyst

knowcompoundsThiaminefindings

Every finding on thiamine

18 findings, by evidence strength

Direction
Strength, at least

18 shown

  1. All-cause mortalitycontestedMoved: lowersEffect, as reportedOR0.37[0.18 to 0.78]Evidence: Moderatereplicated ×9Paper: PMID 341932352021
    Who
    Critically ill adults with COVID-19 in two ICUs, retrospective cohort; adjunctive thiamine versus none, propensity-score matched (83 pairs); horizon is 30 days
    Dose studied
    not reported

    In other words, patients who received thiamine as adjunctive therapy during ICU stay had a lower 30-day mortality rate by 63% [OR (95% CI): 0.37 (0.18, 0.78), P value = 0.009] (Table 1).”

    Quoted verbatim from Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study.cohortPermalink
  2. Fasting blood glucoseMoved: no difference foundEffect, as reportedMD−0.2[−0.69 to 0.29]Evidence: ModeratePaper: PMID 360080642022
    Who
    Adults with type 2 diabetes; three pooled placebo-controlled trials; follow-up under 3 months
    Dose studied
    not reported

    Pooled results from three trials demonstrated no statistically significant difference in the FBG level between those who received thiamine supplementation versus placebo after less than 3 months of follow-up (MD, −0.20 mmol/L; CI: −0.69 to 0.29).”

    Quoted verbatim from Effect of thiamine supplementation on glycaemic outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.meta-analysisPermalink
  3. All-cause mortalitycontestedMoved: lowersEvidence: Moderatereplicated ×9Paper: PMID 288509302018
    Who
    Adults with septic shock and alcohol use disorder in an ICU (retrospective, unadjusted comparison); thiamine-treated patients versus patients given no thiamine; routes pooled (68% of initial doses parenteral, remainder oral)
    Dose studied
    most commonly 100 mg per dose

    We found a significantly lower mortality for those receiving thiamine compared to those not receiving thiamine (15 [44%] vs. 15 [79%], p = 0.02, Table 2).”

    Quoted verbatim from Thiamine in septic shock patients with alcohol use disorders: An observational pilot study.cohortPermalink
  4. All-cause mortalitycontestedMoved: lowersEvidence: Moderatereplicated ×9Paper: PMID 418724382026
    Who
    Adult ICU patients with sepsis-associated delirium (Sepsis-3, MIMIC-IV, liver disease excluded); 332 received thiamine, 956 did not; crude unadjusted analysis, 30-day follow-up
    Dose studied
    not reported

    In crude analysis, thiamine use was associated with a lower risk of 30-day mortality.”

    Quoted verbatim from Association of thiamine supplementation with 30-day mortality among ICU patients with sepsis-associated delirium.cohort · 4 weeksPermalink
  5. Glycated haemoglobin (HbA1c)Moved: no difference foundEffect, as reportedMD−0.02[−0.35 to 0.31]Evidence: ModeratePaper: PMID 360080642022
    Who
    Adults with type 2 diabetes; two pooled placebo-controlled trials; follow-up under 3 months
    Dose studied
    not reported

    Two trials that investigated the effect of thiamine supplementation versus placebo on HbA1c levels demonstrated no statistically significant differences between the groups at less than 3-month follow-up period (mean difference, MD: −0.02%, 95% CI: −0.35 to 0.31).”

    Quoted verbatim from Effect of thiamine supplementation on glycaemic outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.meta-analysisPermalink
  6. All-cause mortalitycontestedMoved: lowersEffect, as reportedHR0.8[0.67 to 0.94]Evidence: Moderatereplicated ×9Paper: PMID 396143572024
    Who
    Adult ICU patients with sepsis or septic shock at two Swiss university hospitals, 2012-2022; B1 group (n = 1054) versus control group on standard treatment without B1 or ascorbic acid (n = 2183); oral and intravenous thiamine pooled; all clusters combined; all-cause in-hospital mortality
    Dose studied
    not reported

    Overall in-hospital mortality was not the same across the three treatment groups, with a lower mortality observed in patients in group B1 compared to the control group (hazard ratio 0.8, 95% confidence interval [0.67;0.94], p = 0.008, Fig. 1 and Supplementary Fig. 2).”

    Quoted verbatim from Differential effects of thiamine and ascorbic acid in clusters of septic patients identified by latent variable analysis.cohortPermalink
  7. All-cause mortalitycontestedMoved: lowersEvidence: Limitedreplicated ×9Paper: PMID 362594602023
    Who
    Adults with Sepsis-3 in the MIMIC-IV intensive care database, retrospective cohort; intravenous thiamine in ICU versus none; confounder-adjusted Cox model; horizon is ICU stay
    Dose studied
    not reported

    In comparison with the TUR group, the TR group had a statistically significantly lower risk of ICU mortality.”

    Quoted verbatim from Thiamine supplementation may be associated with improved prognosis in patients with sepsis.cohortPermalink
  8. All-cause mortalitycontestedMoved: lowersEffect, as reportedHR0.82[0.69 to 0.98]Evidence: Limitedreplicated ×9Paper: PMID 411847852025
    Who
    Critically ill patients with cerebrovascular disease in the MIMIC-IV database, propensity-score-matched thiamine users and non-users (1,585 matched pairs); 28-day all-cause mortality shown
    Dose studied
    not reported

    With 1,585 matched pairs post-PSM, thiamine administration showed a significant association with decreased mortality at 7 days (HR = 0.68, 95%CI: 0.53-0.89, P = 0.004), 14 days (HR = 0.78, 95%CI: 0.64-0.96, P = 0.016), and 28 days (HR = 0.82, 95%CI: 0.69-0.98, P = 0.028) compared with non-thiamine use after adjustment.”

    Quoted verbatim from Thiamine use and short-term prognosis in critical cerebrovascular disease: a propensity score matched retrospective analysis from the MIMIC-IV database.cohort · 4 weeksPermalink
  9. All-cause mortalitycontestedMoved: lowersEvidence: Very limitedreplicated ×9Paper: PMID 422519132026
    Who
    Critically ill adults with sepsis-associated acute respiratory failure in the MIMIC-IV database; thiamine supplementation versus no thiamine, retrospective
    Dose studied
    not reported

    Thiamine supplementation was independently associated with reduced in-hospital and ICU mortality in critically ill patients with sepsis-associated acute respiratory failure, particularly in the elderly.”

    Quoted verbatim from The association between thiamine use and mortality in critically ill patients with sepsis-associated acute respiratory failure: A retrospective analysis of the MIMIC-IV database.cohortPermalink
  10. Incidence of ICU deliriumMoved: lowersEffect, as reportedOR0.58[0.34 to 0.98]Evidence: Very limitedPaper: PMID 341185012021
    Who
    Critically ill patients; RCT-only subset of a meta-analysis that also pooled cohort studies, thiamine versus standard of care
    Dose studied
    not reported

    In the analysis of RCTs, thiamine supplementation showed 42% lower odds of developing ICU delirium (OR 0.58, 95% CI, 0.34-0.98).”

    Quoted verbatim from Effect of thiamine supplementation in critically ill patients: A systematic review and meta-analysis.meta-analysisPermalink
  11. All-cause mortalitycontestedMoved: no difference foundEffect, as reportedOR0.87[0.62 to 1.21]Evidence: Very limitedreplicated ×1Paper: PMID 330368542020
    Who
    Patients with septic shock; pooled four randomized controlled trials of intravenous thiamine
    Dose studied
    not reported

    Overall, compared with control group in patients with septic shock, intravenous thiamine revealed no substantial impact on mortality (odd ratio [OR] = 0.87; 95% confidence interval [CI) = 0.62 to 1.21; P = 0.40), lactate change (standard mean difference [SMD] = 0.04; 95% CI = -0.28 to 0.35; P = 0.82), Sequential Organ Failure Assessment (SOFA) change (SMD = 0.02; 95% CI = -0.18 to 0.21; P = 0.87), intensive care unit (ICU) stay (SMD = -0.02; 95% CI = -0.33 to 0.30; P = 0.90) or renal replacement therapy (OR = 0.47; 95% CI = 0.07 to 3.15; P = 0.43).”

    Quoted verbatim from Intravenous thiamine for septic shock: A meta-analysis of randomized controlled trials.meta-analysisPermalink
  12. Intensive care unit length of staycontestedMoved: raisesEffect, as reportedMD0.4[0.01 to 0.79]Evidence: Very limitedPaper: PMID 393070942024
    Who
    Critically ill patients; meta-analysis of randomized controlled trials of intravenous thiamine
    Dose studied
    not reported

    Conversely, thiamine administration resulted in a slight increase in the length of ICU stay (MD, 0.40 days; 95% CI, 0.01-0.79 days; High CoE).”

    Quoted verbatim from Effect of intravenous thiamine administration on critically ill patients: A systematic review and meta-analysis of randomized controlled trials.meta-analysisPermalink
  13. All-cause mortalitycontestedMoved: lowersEffect, as reportedHR0.666[0.49 to 0.905]Evidence: Very limitedreplicated ×9Paper: PMID 300283622018
    Who
    Adults with septic shock admitted to medicine or surgery ICU; 123 thiamine-treated patients matched with 246 patients not receiving thiamine; retrospective single-center matched cohort
    Dose studied
    IV thiamine within 24 hours of hospital admission

    Thiamine administration was also associated with a reduction in 28-day mortality (hazard ratio, 0.666; 95% CI, 0.490-0.905).”

    Quoted verbatim from Effect of Thiamine Administration on Lactate Clearance and Mortality in Patients With Septic Shock.cohort · 4 weeksPermalink
  14. All-cause mortalitycontestedMoved: no difference foundEvidence: Very limitedreplicated ×1Paper: PMID 326974832020
    Who
    Patients with septic shock requiring norepinephrine within 2 days of admission, Japanese nationwide database; thiamine 100 mg or more within 2 days of admission versus no thiamine, inverse probability of treatment weighting
    Dose studied
    100 mg or 200 mg per day within 2 days of admission

    The findings of this nationwide database-based observational study did not support an association between thiamine administration early after admission and the 28-day mortality in patients with septic shock.”

    Quoted verbatim from Association Between IV Thiamine and Mortality in Patients With Septic Shock: A Nationwide Observational Study.cohort · 4 weeksPermalink
  15. Intensive care unit length of staycontestedMoved: no difference foundEffect, as reportedSMD−0.02[−0.33 to 0.3]Evidence: Very limitedPaper: PMID 330368542020
    Who
    Patients with septic shock; pooled four randomized controlled trials of intravenous thiamine
    Dose studied
    not reported

    Overall, compared with control group in patients with septic shock, intravenous thiamine revealed no substantial impact on mortality (odd ratio [OR] = 0.87; 95% confidence interval [CI) = 0.62 to 1.21; P = 0.40), lactate change (standard mean difference [SMD] = 0.04; 95% CI = -0.28 to 0.35; P = 0.82), Sequential Organ Failure Assessment (SOFA) change (SMD = 0.02; 95% CI = -0.18 to 0.21; P = 0.87), intensive care unit (ICU) stay (SMD = -0.02; 95% CI = -0.33 to 0.30; P = 0.90) or renal replacement therapy (OR = 0.47; 95% CI = 0.07 to 3.15; P = 0.43).”

    Quoted verbatim from Intravenous thiamine for septic shock: A meta-analysis of randomized controlled trials.meta-analysisPermalink
  16. Subjective fatigueMoved: lowersEvidence: Very limitedPaper: PMID 332102992021
    Who
    Patients with quiescent inflammatory bowel disease and severe chronic fatigue with no other explanation for it; placebo-controlled crossover, fatigue measured on the Inflammatory Bowel Disease-Fatigue Questionnaire
    Dose studied
    high-dose oral thiamine 600-1800 mg/d by gender and weight, 4 weeks

    Crossover analysis showed a mean reduction of 4.5 points (95% CI 2.6-6.2) in fatigue after thiamine compared with a mean increase of 0.75 point (95% CI -1.3-2.8; P = 0.0003) after placebo.”

    Quoted verbatim from Randomised clinical trial: high-dose oral thiamine versus placebo for chronic fatigue in patients with quiescent inflammatory bowel disease.crossover · 4 weeksPermalink
  17. All-cause mortalitycontestedMoved: lowersEffect, as reportedOR0.046[0.002 to 0.86]Evidence: Very limitedreplicated ×9Paper: PMID 378804702024
    Who
    Infants (median age 4 months) admitted with acute non-infectious encephalopathy to a hospital in Sikkim; thiamine-treated versus untreated patients, retrospective
    Dose studied
    not reported

    Thiamine treatment was significantly associated with reduced odds of mortality (aOR 0.046, 95% CI 0.0024-0.86, p 0.039).”

    Quoted verbatim from Thiamine Responsive Acute Infantile Encephalopathy.cohortPermalink
  18. All-cause mortalitycontestedMoved: lowersEffect, as reportedOR0.58[0.45 to 0.74]Evidence: Very limitedreplicated ×9Paper: PMID 343928482022
    Who
    Critically ill adults with acute kidney injury in the MIMIC III database, propensity-score matched; early thiamine (within 48 h of ICU admission) versus none; 90-day horizon
    Dose studied
    not reported

    Early thiamine use was associated with lower in-hospital mortality (OR 0·65; 95 % CI 0·49, 0·87; P < 0·001) and 90-d mortality (OR 0·58; 95 % CI 0·45, 0·74; P < 0·001), and it was also associated with the recovery of renal function (OR 1·26; 95 % CI 1·17, 1·36; P < 0·001).”

    Quoted verbatim from Associations between early thiamine administration and clinical outcomes in critically ill patients with acute kidney injury.cohort · 3 monthsPermalink

No dose is advised.